A case of lung adenocarcinoma harboring exon 19 EGFR deletion and EML4-ALK fusion gene

Lung Cancer

Volumn 81, Issue 2, 2013, Pages 308-310

  Chen, Xiaoxia ^a   Zhang, Jie ^a   Hu, Qiong ^a   Li, Xuefei ^a   Zhou, Caicun ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Acquired resistance; Adenocarcinoma; EGFR mutation; EML4 ALK fusion; Lung

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CISPLATIN; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; MICROTUBULE ASSOCIATED PROTEIN;

ADULT; ARTICLE; BRONCHOSCOPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; ECHINODERM; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE DELETION; GENE TRANSLOCATION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LYMPH NODE; MALE; PATIENT REFERRAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REPEAT PROCEDURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOKING; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TUMOR BIOPSY;

ACQUIRED RESISTANCE; ADENOCARCINOMA; EGFR MUTATION; EML4-ALK FUSION; LUNG;

ADENOCARCINOMA; EXONS; GENE DELETION; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84879890014     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.05.003     Document Type: Article

References (11)

1. Kuo Y.W., Wu S.G., Ho C.C., Shih J.Y. Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation. J Thorac Oncol 2010, 5(12):2039-2040.
2. Popat S., de Vieira Araújo A., Min T., Swansbury J., Dainton M., Wotherspoon A., et al. Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib. J Thorac Oncol 2011, 6(11):1962-1963.
3. Tiseo M., Gelsomino F., Boggiani D., Bortesi B., Bartolotti M., Bozzetti C., et al. EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. Lung Cancer 2011, 71(2):241-243.
4. Zhang X., Zhang S., Yang X., Yang J., Zhou Q., Yin L., et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer 2010, 9:188.
5. Tanaka H., Hayashi A., Morimoto T., Taima K., Tanaka Y., Shimada M., et al. A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene. BMC Cancer. 2012, 12:558.
6. Zhou C., Wu Y.L., Chen G., Feng J., Liu X.Q., Wang C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12(8):735-742.
7. Wu J.Y., Wu S.G., Yang C.H., Chang Y.L., Chang Y.C., Hsu Y.C., et al. Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations. Lung Cancer 2011, 72(2):205-212.
8. Zhou Q., Zhang X.C., Chen Z.H., Yin X.L., Yang J.J., Xu C.R., et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol 2011, 29(24):3316-3321.
9. Yu H.A., Arcila M.E., Rekhtman N., Sima C.S., Zakowski M.F., Pao W., et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013, 19(8):2240-2247.
10. Sequist L.V., Waltman B.A., Dias-Santagata D., Digumarthy S., Turke A.B., Fidias P., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3(75):ra26.
11. Doebele R.C., Pilling A.B., Aisner D.L., Kutateladze T.G., Le A.T., Weickhardt A.J., et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012, 18(5):1472-1482.